Overall, 178 of 264 individuals (67.4%) had triple-negative breast cancer, 75 (28.4%) had ER- and/or PR-positive ERBB2-negative breast cancer, and 11 (4.2%) had ERBB2-positive breast cancer. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.